Skip to content
Synopulse
  • The Brief
    • Quick
    • In Depth
    • Editor’s Pick
    • Findings
  • Reports
    • The beats
      • Catalyst
      • AccessWatch
      • DealPulse Signal
      • DealPulse Report
    • Analysis
      • The Throughline
      • The Top Line
      • The Forecast
    • Coverage
      • ShowFloor
      • The Arena
  • The Pulse
    • NeuroPulse
    • OrphanPulse
  • Topics
    • By subject
      • Deals
      • Regulatory
      • Market Access
      • Pricing & Reimbursement
      • Legal & Policy
    • By technology
      • Antibody
      • Cell & Gene Tx
      • Drug conjugates
      • AI/ML
      • Digital Health
      • Radiopharma
    • By therapy area
      • Neurology
      • Oncology
      • Rare Diseases
      • Cardio-Metabolic
      • Immunology & Inflammation
      • Orthopaedics
The Number Everyone Will Quote About European Launches Rests on Eleven Products
The Number Everyone Will Quote About European Launches Rests on Eleven Products
Athithi Verma August 21, 2026
The 22.9% figure driving coverage of European launch delays is 48 products falling to 37. The pricing finding underneath it is stronger and barely quoted.
Singapore Approved Both Blenrep Combinations. Korea Reimbursed Only the One With Survival Data.
Singapore Approved Both Blenrep Combinations. Korea Reimbursed Only the One With Survival Data.
A KAIST Barrier Chip Separated Three Glioblastoma Patients That MGMT Testing Called Identical
A KAIST Barrier Chip Separated Three Glioblastoma Patients That MGMT Testing Called Identical
Two FDA Device Authorisations, Two Sets of Evidence Narrower Than the Headline
Two FDA Device Authorisations, Two Sets of Evidence Narrower Than the Headline
Two First-Ever Rare Disease Approvals Landed the Same Day. Both Were Measured by Proxy.
Two First-Ever Rare Disease Approvals Landed the Same Day. Both Were Measured by Proxy.
A UC Irvine Team Names Five Mitochondrial Drug Classes for CAR-T Neurotoxicity and Says Nobody Is Testing Any of Them
A UC Irvine Team Names Five Mitochondrial Drug Classes for CAR-T Neurotoxicity and Says Nobody Is Testing Any of Them

Editor’s Pick

In Japan, Expanding a Label Is What Triggers the Price Cut

In Japan, Expanding a Label Is What Triggers the Price Cut

AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.

AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.

Congress Exempted the Medically Frail. The Coding System Cannot Find Them.

Congress Exempted the Medically Frail. The Coding System Cannot Find Them.

NeuroPulse


NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It Yet

NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It Yet

OrphanPulse


OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later

OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later

OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029

OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029

DealPulse Signal


DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Report


DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

The Beats


DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

Analysis


Reshaping Pharma by 2027

7 Market Access Trends Reshaping Pharmaย by 2027

The Biologics Patent Cliff: Inside Pharma's 2026-2029 Reckoning

The Biologics Patent Cliff: Inside Pharma’s 2026-2029 Reckoning

Coverage


The ADC Decade Accelerates What to Watch at ASCO 2026

The ADC Decade Accelerates: What to Watch at ASCO 2026

The Briefs

The Number Everyone Will Quote About European Launches Rests on Eleven Products

The Number Everyone Will Quote About European Launches Rests on Eleven Products

Athithi Verma August 21, 2026
Singapore Approved Both Blenrep Combinations. Korea Reimbursed Only the One With Survival Data.

Singapore Approved Both Blenrep Combinations. Korea Reimbursed Only the One With Survival Data.

Athithi Verma August 21, 2026
A KAIST Barrier Chip Separated Three Glioblastoma Patients That MGMT Testing Called Identical

A KAIST Barrier Chip Separated Three Glioblastoma Patients That MGMT Testing Called Identical

Athithi Verma August 21, 2026
Two FDA Device Authorisations, Two Sets of Evidence Narrower Than the Headline

Two FDA Device Authorisations, Two Sets of Evidence Narrower Than the Headline

Athithi Verma August 21, 2026
Two First-Ever Rare Disease Approvals Landed the Same Day. Both Were Measured by Proxy.

Two First-Ever Rare Disease Approvals Landed the Same Day. Both Were Measured by Proxy.

Athithi Verma August 21, 2026
A UC Irvine Team Names Five Mitochondrial Drug Classes for CAR-T Neurotoxicity and Says Nobody Is Testing Any of Them

A UC Irvine Team Names Five Mitochondrial Drug Classes for CAR-T Neurotoxicity and Says Nobody Is Testing Any of Them

Athithi Verma August 20, 2026
Read More
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress